603439.SHG Guizhou Sanli Pharmaceutical Co Ltd
- Market cap
- CNY 4.55B
- P/E
- 86.6x
- P/B
- 2.88x
- ROE
- 7.7%
- Dividend yield
- 3.55%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 603439.SHG undervalued?
Graham numberThe Graham number of Guizhou Sanli Pharmaceutical Co Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Guizhou Sanli Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Guizhou Sanli Pharmaceutical Co Ltd yet.
Guizhou Sanli Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Guizhou Sanli Pharmaceutical Co Ltd
Guizhou Sanli Pharmaceutical Co.,Ltd, together with its subsidiaries, engages in the plantation, research, development, production, and sale of pharmaceutical products in China. The company offers respiratory system, tonifying, gynecological, and orthopedic medications, as well as cardiovascular and cerebrovascular drugs, and other medicines. It also provides products in various dosage forms, including sprays, granules, capsules, pills, tablets, medicated wines, and ointment…
Full company profileGuizhou Sanli Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Guizhou Sanli Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 515M | 638M | 722M | 884M | 630M | 939M | 1.20B | 1.63B | 2.14B | 1.70B | 1.30B |
| Gross Profit | 335M | 424M | 473M | 585M | 421M | 662M | 862M | 1.20B | 1.49B | 1.19B | 926M |
| Operating Income | 66.6M | 87.5M | 99.8M | 155M | 112M | 179M | 226M | 336M | 326M | 199M | 169M |
| EBITDA | 94.3M | 111M | 138M | 164M | 120M | 196M | 244M | 375M | 414M | 153M | 158M |
| Net Income | 74.9M | 87.6M | 110M | 133M | 94.0M | 152M | 201M | 293M | 274M | 46.3M | 117M |
| EPS | 0.22 | 0.24 | 0.30 | 0.36 | 0.24 | 0.37 | 0.49 | 0.71 | 0.67 | 0.11 | 0.29 |
| Balance Sheet | |||||||||||
| Total Assets | 518M | 565M | 577M | 731M | 1.26B | 1.40B | 1.82B | 2.92B | 3.19B | 2.85B | 2.71B |
| Total Liabilities | 87.4M | 92.1M | 58.7M | 79.7M | 277M | 373M | 578M | 1.21B | 1.60B | 1.34B | 1.13B |
| Shareholders' Equity | 431M | 473M | 518M | 651M | 982M | 1.03B | 1.24B | 1.47B | 1.53B | 1.45B | 1.52B |
| Cash & Short-term Investments | 177M | 180M | 131M | 240M | 450M | 642M | 631M | 623M | 498M | 389M | 187M |
| Total Debt | - | - | - | - | 200M | 200M | 206M | 610M | 561M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 35.1M | 57.5M | 75.3M | 116M | 63.2M | 155M | 293M | 277M | 107M | 165M | - |
| Capital Expenditure | 12.4M | 7.17M | 1.78M | 8.01M | 51.7M | 26.1M | 120M | 109M | 45.2M | 25.8M | 27.8M |
| Free Cash Flow | 22.7M | 50.3M | 73.6M | 108M | 11.5M | 129M | 173M | 168M | 61.9M | 139M | 91.1M |
| Ratios | |||||||||||
| ROE | 17.4% | 18.5% | 21.3% | 20.4% | 9.6% | 14.8% | 16.2% | 19.9% | 17.9% | 3.2% | 7.7% |
| ROA | 14.5% | 15.5% | 19.2% | 18.2% | 7.5% | 10.8% | 11.1% | 10.0% | 8.6% | 1.6% | 4.3% |
| Net Profit Margin | 14.6% | 13.7% | 15.3% | 15.1% | 14.9% | 16.2% | 16.8% | 17.9% | 12.8% | 2.7% | 9.0% |
| Debt to Equity | - | - | - | - | 0.20x | 0.19x | 0.17x | 0.41x | 0.37x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Guizhou Sanli Pharmaceutical Co Ltd dividends
- Dividend yield
- 3.55%
- Forward dividend
- 0.06 CNY
- Payout ratio
- 349.0%
- Ex-dividend date
- Jun 30, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 161M | 0.39 | 349.0% |
| 2024 | CNY 104M | 0.25 | 38.0% |
| 2023 | CNY 41.0M | 0.10 | 14.0% |
| 2022 | CNY 8.92M | 0.02 | 4.4% |
| 2021 | CNY 102M | 0.25 | 66.9% |
| 2020 | CNY 2.62M | 0.01 | 2.8% |
| 2019 | CNY 110M | 0.30 | 82.8% |
| 2018 | CNY 70.4M | 0.19 | 63.7% |
| 2017 | CNY 44.9M | 0.12 | 51.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Guizhou Sanli Pharmaceutical Co Ltd
- Insiders 59.41%
- Institutions 1.47%
- Public & others 39.12%
- Shares outstanding 404M
- Free float 160M
Guizhou Sanli Pharmaceutical Co Ltd company profile
- Company name
- Guizhou Sanli Pharmaceutical Co Ltd
- Ticker
- 603439.SHG
- ISIN
- CNE1000040B4
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,887
- Fiscal year end
- December
- Address
- Xiayun Industrial Park, Anshun, China, 561000
- Phone
- 86 851 3811 3572
- Website
- gz-sanli.com
About Guizhou Sanli Pharmaceutical Co Ltd
Guizhou Sanli Pharmaceutical Co.,Ltd, together with its subsidiaries, engages in the plantation, research, development, production, and sale of pharmaceutical products in China. The company offers respiratory system, tonifying, gynecological, and orthopedic medications, as well as cardiovascular and cerebrovascular drugs, and other medicines. It also provides products in various dosage forms, including sprays, granules, capsules, pills, tablets, medicated wines, and ointments. In addition, the company trades medicinal herbs. Guizhou Sanli Pharmaceutical Co.,Ltd was founded in 1995 and is based in Anshun, China.
Guizhou Sanli Pharmaceutical Co Ltd management
9- Mr. Qianfan ZhangGM, Vice Chairman · born 1986
- Mr. Jue Ben WangVice Chairman & Deputy GM · born 1986
- Ms. Ke GuoFinancial Director, Accounting Supervisor & Director · born 1987
- Mr. Yi WangDeputy GM & Director · born 1988
- Mr. Yuan YuDeputy General Manager · born 1982
- Mr. Zhiyu YangDeputy General Manager · born 1986
- Mr. Li DengDeputy General Manager · born 1985
- Mr. Zhan Biao LuoDeputy General Manager · born 1978
- Ms. Jing LongManager of Human Resources Department · born 1985